In comparison, PTGR1 expression is entirely independent of mutations in KRAS, TP53 and STK11 which are commonly altered in NSCLC but currently lack effective targeted therapy options (Supplementary Figure 15). This evidence concerns the gene PTGR1 and non-small cell lung carcinoma.